Venous thromboembolism after hip arthroscopy: a systematic review of incidence, risk factors, and international guidelines
Research article published in Frontiers in surgery (2025)
Abstract
PURPOSE: This review aims to systematically evaluate the incidence, risk factors, and international guideline discrepancies for venous thromboembolism (VTE) following hip arthroscopy (HA). METHODOLOGY: A search of four databases from the inception to April 20, 2025, identified studies reporting VTE outcomes post-HA. Relevant practice guideline recommendations were concurrently analyzed. RESULTS: Twenty-one studies encompassing 135,377 patients and five clinical guidelines were included. Female patients constituted 91,013 cases (67.2%). The mean patient age was 37.08 years; however, the average follow-up duration was limited to 3.7 months, which may be a study limitation. Pooled incidence rates were: deep vein thrombosis (DVT) 0.441%, pulmonary embolism (PE) 0.216%, and overall VTE 0.656%. The majority of studies were Level IV evidence (57%), with Level III evidence comprising 33%. Identified risk factors for post-HA VTE included obesity, oral contraceptive use, ≥45 years, overweight status, coagulopathy, and arteriovenous anomalies. The reported VTE incidence ranged from 0% to 6.94%. International guidelines vary, but most advocate for risk-stratified thromboprophylaxis. CONCLUSIONS: The incidence of VTE following hip arthroscopy is low. Routine pharmacological thromboprophylaxis may not be necessary for standard-risk patients. However, high-risk individuals warrant personalized prophylaxis regimens, with pharmacological prophylaxis when clinically indicated based on risk assessment.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This systematic review of 21 studies (135,377 patients) and five guidelines found a low pooled incidence of venous thromboembolism after hip arthroscopy (DVT 0.441%, PE 0.216%, overall VTE 0.656%), identified risk factors such as obesity, oral contraceptive use, and age, and concluded that routine pharmacologic thromboprophylaxis may be unnecessary for standard-risk patients while high-risk individuals warrant personalized prophylaxis. For hirudotherapy this provides context on risk-stratified antithrombotic decision-making in surgery — the same individualized risk-benefit framing that should govern any consideration of anticoagulant exposure, including local leech-derived effects, around procedures. The caveat is that the included evidence was predominantly low-level (Level IV/III) with short follow-up, and the review concerns conventional pharmacologic thromboprophylaxis with no leech component, so it informs general surgical anticoagulation context only.
Citation
Venous thromboembolism after hip arthroscopy: a systematic review of incidence, risk factors, and international guidelines.
Gao et al. · Frontiers in surgery, 2025
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026